“Targeting Cardiometabolic Risk Beyond Statins: A Systematic Review of Evolocumab in Statin-Intolerant Patients with Metabolic Syndrome”, JOC, vol. 24, no. 3s, pp. 441–448, Sep. 2025, doi: 10.64149/J.Carcinog.24.3s.441-448.